Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 475

1.

Chromosome 1p/19q status combined with expression of p53 protein improves the diagnostic and prognostic evaluation of oligodendrogliomas.

Xiong J, Liu Y, Wang Y, Ke RH, Mao Y, Ye ZR.

Chin Med J (Engl). 2010 Dec;123(24):3566-73.

PMID:
22166632
2.

Correlation of chromosomes 1p and 19q status and expressions of O6-methylguanine DNA methyltransferase (MGMT), p53 and Ki-67 in diffuse gliomas of World Health Organization (WHO) grades II and III: a clinicopathological study.

Huang L, Jiang T, Yuan F, Li GL, Cui Y, Liu EZ, Wang ZC.

Neuropathol Appl Neurobiol. 2009 Aug;35(4):367-79. doi: 10.1111/j.1365-2990.2008.01002.x. Epub 2008 Nov 18.

PMID:
19019173
3.

[Correlation between loss of heterozygosity on chromosome 1p and 19q and expression of MGMT, p53 and Ki-67 proteins in gliomas].

Huang L, Jiang T, Yuan F, Li GL, Xu LX, Cui Y.

Zhonghua Zhong Liu Za Zhi. 2011 Oct;33(10):752-8. Chinese.

PMID:
22335907
5.

Longitudinal assessment of genetic and epigenetic markers in oligodendrogliomas.

Lavon I, Zrihan D, Zelikovitch B, Fellig Y, Fuchs D, Soffer D, Siegal T.

Clin Cancer Res. 2007 Mar 1;13(5):1429-37.

6.

Molecular prognostic factors of anaplastic oligodendroglial tumors and its relationship: a single institutional review of 77 patients from China.

Li S, Yan C, Huang L, Qiu X, Wang Z, Jiang T.

Neuro Oncol. 2012 Jan;14(1):109-16. doi: 10.1093/neuonc/nor185. Epub 2011 Oct 27.

8.

Prognostic value of isocitrate dehydrogenase 1, O6-methylguanine-DNA methyltransferase promoter methylation, and 1p19q co-deletion in Japanese malignant glioma patients.

Takahashi Y, Nakamura H, Makino K, Hide T, Muta D, Kamada H, Kuratsu J.

World J Surg Oncol. 2013 Oct 25;11:284. doi: 10.1186/1477-7819-11-284.

9.

IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor Group.

van den Bent MJ, Dubbink HJ, Marie Y, Brandes AA, Taphoorn MJ, Wesseling P, Frenay M, Tijssen CC, Lacombe D, Idbaih A, van Marion R, Kros JM, Dinjens WN, Gorlia T, Sanson M.

Clin Cancer Res. 2010 Mar 1;16(5):1597-604. doi: 10.1158/1078-0432.CCR-09-2902. Epub 2010 Feb 16.

10.

Oligodendroglial tumors: refinement of candidate regions on chromosome arm 1p and correlation of 1p/19q status with survival.

Felsberg J, Erkwoh A, Sabel MC, Kirsch L, Fimmers R, Blaschke B, Schlegel U, Schramm J, Wiestler OD, Reifenberger G.

Brain Pathol. 2004 Apr;14(2):121-30.

PMID:
15193024
11.

Phenotype versus genotype correlation in oligodendrogliomas and low-grade diffuse astrocytomas.

Watanabe T, Nakamura M, Kros JM, Burkhard C, Yonekawa Y, Kleihues P, Ohgaki H.

Acta Neuropathol. 2002 Mar;103(3):267-75. Epub 2001 Nov 22.

PMID:
11907807
12.

[Loss of heterozygosity of chromosome 1p/19q and p53 protein expression in oligodendroglioma].

Xiong J, Liu Y, Li C, Zhu JJ, Ye ZR, Mao Y, Wang Y.

Zhonghua Bing Li Xue Za Zhi. 2009 Jul;38(7):445-50. Chinese.

PMID:
19781190
13.

Survival analysis of presumptive prognostic markers among oligodendrogliomas.

McLendon RE, Herndon JE 2nd, West B, Reardon D, Wiltshire R, Rasheed BK, Quinn J, Friedman HS, Friedman AH, Bigner DD.

Cancer. 2005 Oct 15;104(8):1693-9.

14.

LOH 19q indicates shorter disease progression-free interval in low-grade oligodendrogliomas with EMP3 methylation.

Pasini A, Iorio P, Bianchi E, Cerasoli S, Cremonini AM, Faedi M, Guarnieri C, Guiducci G, Riccioni L, Molinari C, Rengucci C, Calistri D, Giordano E.

Oncol Rep. 2012 Dec;28(6):2271-7. doi: 10.3892/or.2012.2047. Epub 2012 Sep 20.

PMID:
22992787
15.

Significance of complete 1p/19q co-deletion, IDH1 mutation and MGMT promoter methylation in gliomas: use with caution.

Boots-Sprenger SH, Sijben A, Rijntjes J, Tops BB, Idema AJ, Rivera AL, Bleeker FE, Gijtenbeek AM, Diefes K, Heathcock L, Aldape KD, Jeuken JW, Wesseling P.

Mod Pathol. 2013 Jul;26(7):922-9. doi: 10.1038/modpathol.2012.166. Epub 2013 Feb 22.

16.

Assessment of 1p/19q status by fluorescence in situ hybridization assay: A comparative study in oligodendroglial, mixed oligoastrocytic and astrocytic tumors.

Shukla B, Agarwal S, Suri V, Pathak P, Sharma MC, Gupta D, Sharma BS, Suri A, Halder A, Sarkar C.

Neurol India. 2009 Sep-Oct;57(5):559-66. doi: 10.4103/0028-3886.57795.

17.

Primary glioblastoma with oligodendroglial differentiation has better clinical outcome but no difference in common biological markers compared with other types of glioblastoma.

Laxton RC, Popov S, Doey L, Jury A, Bhangoo R, Gullan R, Chandler C, Brazil L, Sadler G, Beaney R, Sibtain N, King A, Bodi I, Jones C, Ashkan K, Al-Sarraj S.

Neuro Oncol. 2013 Dec;15(12):1635-43. doi: 10.1093/neuonc/not125. Epub 2013 Oct 24.

18.

Hsp27 (HSPB1): a possible surrogate molecular marker for loss of heterozygosity (LOH) of chromosome 1p in oligodendrogliomas but not in astrocytomas.

Castro GN, Cayado-Gutiérrez N, Moncalero VL, Lima P, De Angelis RL, Chávez V, Cuello-Carrión FD, Ciocca DR.

Cell Stress Chaperones. 2012 Nov;17(6):779-90. doi: 10.1007/s12192-012-0350-6. Epub 2012 Jul 18.

19.

MGMT promoter methylation is prognostic but not predictive for outcome to adjuvant PCV chemotherapy in anaplastic oligodendroglial tumors: a report from EORTC Brain Tumor Group Study 26951.

van den Bent MJ, Dubbink HJ, Sanson M, van der Lee-Haarloo CR, Hegi M, Jeuken JW, Ibdaih A, Brandes AA, Taphoorn MJ, Frenay M, Lacombe D, Gorlia T, Dinjens WN, Kros JM.

J Clin Oncol. 2009 Dec 10;27(35):5881-6. doi: 10.1200/JCO.2009.24.1034. Epub 2009 Nov 9.

20.

Is the 1p/19q deletion a diagnostic marker of oligodendrogliomas?

Gadji M, Fortin D, Tsanaclis AM, Drouin R.

Cancer Genet Cytogenet. 2009 Oct;194(1):12-22. doi: 10.1016/j.cancergencyto.2009.05.004.

PMID:
19737649

Supplemental Content

Support Center